Clinical trials: Clear Cell Kidney Cancer
Renal Cell Carcinoma
NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
The purpose of this study is to see how well the study drug, axitinib, helps control renal (kidney) cancer that has come back (recurrent) or spread (metastatic).
- Trial name
- PrE0801 (NCT01649180)
- Testing
- Axitinib
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- PrECOG, LLC.
Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1
ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)
Renal cell carcinoma (RCC) is the 9th most common cancer in Australia, the 10th most common cancer in Western populations.~75% of kidney cancers are clear-cell renal cell carcinomas (ccRCC).
- Conditions
- Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1, Papillary Renal Cell Carcinoma Type 2, Chromophobe Renal Cell Carcinoma
- Trial name
- UNICAB (NCT03685448)
- Testing
- Cabozantinib
- Where
- 11 sites in Australia
- Volunteers
- 35 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Clear Cell Renal Cell Carcinoma
A Small-molecule Carbonic Anhydrase IX Targeting PET Tracer in Clear Cell Renal Cell Carcinoma
The goal of this pilot clinical trial is to see the potential application of a CAIX targeted PET. tracer in patients with clear cell renal cell carcinoma.
- Trial name
- NCT05728515
- Testing
- 68Ga-NY104
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
The goal of this research study is to evaluate how well and safely the study drugs sasanlimab, palbociclib, and axitinib work for treatment of participants with advanced clear cell renal cell carcinoma (ccRCC) or translocation…
- Conditions
- Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
- Trial name
- SPARCC (NCT07123090)
- Testing
- Sasanlimab, Palbociclib, Axitinib
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Stephanie Berg
Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
This phase I trial studies the side effects and best dose of aldesleukin when given together with pembrolizumab in treating patients with kidney cancer that has spread to other parts of the body.
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- NCT03260504
- Testing
- Aldesleukin, Pembrolizumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Clear-cell Renal Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma
Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus
Disease and Stage: Metastatic and locally advanced clear cell renal carcinoma An open-label, exploratory, single-arm, multicenter trial.
- Trial name
- NEORAD (NCT01715935)
- Testing
- Everolimus
- Where
- 10 sites in France
- Volunteers
- 25 people
- Sponsor
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Chromophobe Renal Cell Carcinoma, Clear Cell Papillary Renal Tumor
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
This study is being done to collect blood, tissue and urine samples to identify a novel high quality methylated DNA marker in patients with renal tumors.
- Conditions
- Chromophobe Renal Cell Carcinoma, Clear Cell Papillary Renal Tumor, Clear Cell Renal Cell Carcinoma, Kidney Oncocytoma
- Trial name
- NCT06339138
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 589 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Neoadjuvant Therapy
A Study on the Safety and Effectiveness of Tislelizumab Combined With Axitinib for Neoadjuvant Treatment of ccRCC
This trial is a single-center clinical trial to evaluate the tumor shrinkage and safety of tislelizumab combined with axitinib in Neoadjuvant therapy of T2-T3N0M0 renal clear cell carcinoma
- Trial name
- NCT05172440
- Testing
- tislelizumab combined with axitinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Hongqian Guo
Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC)
Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC
Through the neoadjuvant treatment with a combination of Pucotenlimab and Vorolanib, it enabled the successful and safe implementation of partial nephrectomy in patients with localized renal cancer, who had indications for…
- Conditions
- Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC), Neoadjuvant Therapy
- Trial name
- NCT07386158
- Testing
- Pucotenlimab combination with Vorolanib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sun Yat-sen University
Renal Cell Carcinoma, First-line Treatment
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
This is a Phase Ib/II, open-label, single arm trial to evaluate the efficacy and safety of AK104 in combination with axitinib as a first-line treatment for advanced/metastatic special pathological subtypes of renal cell carcinoma…
- Conditions
- Renal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
- Trial name
- NCT05808608
- Testing
- AK104, Axitinib
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Hao Zeng
ccRCC, Renal Cell Carcinoma (Kidney Cancer)
Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC
Multicenter Phase 3 study of 177Lu-TLX250 in adult participants with CAIX-expressing advanced, relapsed or recurrent clear cell renal cell carcinoma (ccRCC).
- Conditions
- ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic
- Trial name
- LUTEON (NCT07197580)
- Testing
- 177Lu-TLX250
- Where
- 5 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Kidney Cancer
Prospective Validation of the Prognostic Value of Long Non-coding MFI2-AS1 RNA in Localized Clear Cell Kidney Cancers
An exploratory analysis of the expression of MFI2-AS1 will be performed at the plasma level with the objective of comparing this expression with tumor tissue.
- Trial name
- MFI2-PREDICT (NCT04946266)
- Testing
- Surgical intervention
- Where
- France
- Volunteers
- 260 people
- Sponsor
- University Hospital, Strasbourg, France
Renal Cell Carcinoma
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
This is a Phase 1b/2a, open-label, multi-center, dose-escalation and safety/efficacy evaluation trial of Pexa-Vec plus Cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC).
- Trial name
- NCT03294083
- Testing
- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 95 people
- Sponsor
- SillaJen, Inc.
Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma
Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study
This study is testing a new medicine called AK112 (Yivoximab) for people with advanced kidney cancer that has spread to other parts of the body (metastatic clear cell renal cell carcinoma).
- Trial name
- NCT07488572
- Testing
- Yivoximab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Brain and Central Nervous System Tumors, Kidney Cancer
MT2004-30: Tomotherapy for Solid Tumors
RATIONALE: A peripheral blood stem cell transplant or bone marrow transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy and image-guided intensity-modulated radiation…
- Conditions
- Brain and Central Nervous System Tumors, Kidney Cancer, Liver Cancer, Retinoblastoma
- Trial name
- NCT00623077
- Testing
- filgrastim, busulfan, etoposide
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Non-Clear Cell Renal Cell Carcinoma (nccRCC)
A Phase III Randomized Controlled Trial of Serplulimab Plus Fruquintinib as Adjuvant Therapy for High-Risk Non-Clear Cell Renal Cell Carcinoma
People with non-clear cell renal cell carcinoma may remain at high risk of cancer recurrence even after surgery has removed all visible disease.
- Trial name
- SerF-ADJ (NCT07904156)
- Testing
- Serplulimab + Fruquintinib
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody PF-04518600 work in treating patients with kidney cancer that has spread to other parts of the body.
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
- Trial name
- NCT03092856
- Testing
- Anti-OX40 Antibody PF-04518600, Axitinib, Laboratory Biomarker Analysis
- Where
- 9 sites in United States
- Volunteers
- 62 people
- Sponsor
- University of Southern California
Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer
Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
RATIONALE: Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pazopanib hydrochloride before surgery may make the tumor smaller and reduce the amount of…
- Conditions
- Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer
- Trial name
- NCT01158521
- Testing
- pazopanib hydrochloride, therapeutic conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Case Comprehensive Cancer Center
Adenocarcinoma Clear Cell
Immunochemotherapy for Metastatic Renal Cell Carcinoma
Immunochemotherapy consisting of IL-2, INF-A, and VBL and 5FU is regarded as the treatment of choice in metastatic renal cell carcinoma.
- Trial name
- NCT00226798
- Testing
- Capecitabine (Xeloda)
- Where
- Israel
- Volunteers
- 45 people
- Sponsor
- Rambam Health Care Campus
Advanced Cancer, Clear Cell Renal Cell Carcinoma
Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC
To learn if giving 177Lu girentuximab in combination with cabozantinib plus nivolumab can help to control advanced clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT05663710
- Testing
- 177Lu girentuximab, Nivolumab, Cabozantinib
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center